Research Progress on the Molecular Regulatory Mechanism of the Rh Blood Group System and Its Clinical Application

doi:10.3969/j.issn.1671-2587.2025.05.019

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2025, Vol. 27 ›› Issue (5): 712-716.DOI: 10.3969/j.issn.1671-2587.2025.05.019

Previous Articles Next Articles

Research Progress on the Molecular Regulatory Mechanism of the Rh Blood Group System and Its Clinical Application

LI Jingqi, QI Shuyuan, GENG Lingyun

Capital Center for Children's Health,Capital Medical University, Beijing 100020

Received:2025-09-02 Revised:2025-09-12 Online:2025-10-20 Published:2025-10-11

Abstract

Abstract: The Rh blood group system is one of the most clinically significant blood group systems. Incompatibility in this system can lead to alloimmunization, resulting in severe adverse reactions such as hemolytic transfusion reactions in patients and hemolytic disease of the fetus and newborn (HDFN), which threaten patient lives. Recent cutting-edge research on RHD and RHCE variants has yielded significant progress, providing not only an impetus for innovating transfusion protocols but also novel strategies for the management of blood resources. This article reviews the latest advances in the distribution of Rh antigens, their molecular basis, clinical applications, and associated technological innovations, with the aim of optimizing transfusion strategies to enhance safety and efficacy.

Key words: Rh blood group system, Basic research, Alloantibody, Variant, Precision transfusion

CLC Number:

R457

LI Jingqi, QI Shuyuan, GENG Lingyun. Research Progress on the Molecular Regulatory Mechanism of the Rh Blood Group System and Its Clinical Application[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(5): 712-716.

References

[1] Claudia S.Cohn.AABB技术手册[M].20版,桂嵘,等主译. 长沙:中南大学出版社,2022.
[2] Red Cell Immunogenetics and Blood Group Terminology [DB/OL]. [2025-09-01]. https://www.isbtweb.org/isbt-working-parties/rcibgt.html
[3] JIN Y M,FU X Y,XIE S H,et al.Establishment and clinical application of Rh blood group bank in the East China Region[J]. Int J Gen Med,2025,18:717-724.
[4] JI Y L,LUO Y L,WEN J Z,et al.Patients with Asian-type DEL can safely be transfused with RhD-positive blood[J]. Blood,2023,141(17):2141-2150.
[5] YIN Q N,FLEGEL W A.DEL in China: the D antigen among serologic RhD-negative individuals[J]. J Transl Med,2021,19(1):439.
[6] TAKASAKI K,FRIEDMAN D F,UTER S,et al.Variant RHD alleles and Rh immunization in patients with sickle cell disease[J]. Br J Haematol,2023,201(6):1220-1228.
[7] PIRENNE F,FLOCH A,DIOP S.Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries[J]. Lancet Haematol,2023,10(6):e468-e476.
[8] YIN Q N,OUCHARI M.Transfusion management of africans with RHD variants in China[J]. Transfus Clin Biol,2023,30(2):287-293.
[9] ABURTO A,ZAPATA D,RETAMALES E,et al.Genotype analysis to clarify RhD variants in discrepant samples of Chilean population[J]. Front Immunol,2023,14:1299639.
[10] 赵桐茂. Rh基因型匹配输血研究进展[J]. 精准医学杂志, 2019,34(4):283-286.
[11] WU P C,LEE Y Q,MÖLLER M,et al. Elucidation of the low-expressing erythroid CR1 phenotype by bioinformatic mining of the GATA1-driven blood-group regulome[J]. Nat Commun,2023,14(1):5001.
[12] ZHANG R,WEN J Z,TANG C J,et al.Identification of a novel variant (c.1-111A>G) located in GATA-1 motif of RHCE proximal promoter in two Chinese patients with the rare D-- phenotype[J]. Transfusion,2025,65(4): 669-675.
[13] SRIVASTAVA K,BUENO M U,FLEGEL W A.Breakpoint regions of an RHD-CE(4-9)-D allele and a rare JK allele in a Pacific Islander individual[J]. Blood Transfus,2024,22(3):189-197.
[14] LI M H,WANG L P,LI A J,et al.Integrated analyses reveal unexpected complex inversion and recombination in RH genes[J]. Blood Adv,2024,8(12):3154-3165.
[15] MOIZ B,SALMAN M,RASHEED S,et al.Recurrent pregnancy loss in a patient with anti-Rh₁₇[J]. Transfus Med,2024,34(1):66-70.
[16] KULKARNI S,MISHRA G,MARU H,et al.Molecular characterization of rare D--/D-- variants in individuals of Indian origin[J]. Blood Transfus,2022,20(1):59-65.
[17] YE L Y,LI M H,YANG Q X,et al.RHD alleles contributing to serologically weak D phenotypes in China: A single-centre study over 10 years[J]. Vox Sang, 2022,117(7):949-957.
[18] FLOCH A,PIRENNE F,BARRAULT A,et al.Insights into anti-D formation in carriers of RhD variants through studies of 3D intraprotein interactions[J]. Transfusion, 2021,61(4):1286-1301.
[19] YANG J,XU J,WANG W,et al.Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets[J]. Signal Transduct Target Ther, 2023,8(1):210.
[20] TRUEBA-GÓMEZ R,ROSENFELD-MANN F,BAPTISTA-GONZÁLEZ H A,et al. Use of computational biology to compare the theoretical tertiary structures of the most common forms of RhCE and RhD[J]. Vox Sang,2023, 118(10):881-890.
[21] WU C L,YI P,TANG B D,et al.A novel RHCE*cE (c.827C>A) allele, containing the single-nucleotide change, encodes altered c/E antigens[J]. Clin Lab,2023, 69(10). DOI:10.7754/Clin.Lab.2023.230411.
[22] WILSON B,DAVISON C L,LOPEZ G H,et al.A cold case of hemolytic disease of the fetus and newborn resolved by genomic sequencing and population studies to define a new antigen in the Rh system[J]. Transfusion, 2024,64(6):1171-1176.
[23] CI X,FAN X X,LV P,et al.Identification of a novel RHCE*Ce (829G>A) allele associated with absence of C and e antigens expression[J]. Transfus Med,2024, 34(5):445-449.
[24] HOWE J G,STACK G.Relationship between immunogenicity and protein structure at amino acid substitution sites of blood group antigens[J]. Blood, 2025, 146(4):504-517.
[25] YANG Q X,LI A J,WANG C,et al.Fully genotyping and screening of clinically important blood-group antigens by MALDI TOF mass spectrometry[J]. Electrophoresis, 2024,45(5/6):548-556.
[26] 黄伯泉,贾双双,温机智,等. 广州地区RhD阴性献血者Del表型及基因型分析[J]. 中国输血杂志,2024,37(8): 859-865.
[27] 梁爽,莫春妍,刘笑阳,等. Junior血型基因检测技术的建立与1例部分DVI.3型且Jr(a-)稀有血型的鉴定[J]. 中华医学遗传学杂志,2024,41(1):52-58.
[28] TOUNSI W A,LENIS V P,TAMMI S M,et al.Rh blood group D antigen genotyping using a portable nanopore-based sequencing device: proof of principle[J]. Clin Chem,2022,68(9):1196-1201.
[29] WAN Y R,ZHANG M Y,LIU Z T,et al.Rapid parallel blood typing on centrifugal microfluidic platform by microcolumn gel immunoassay[J]. Talanta,2025,282:126959.
[30] CHOMEAN S,BUNNUN P,AUTTAPONG J,et al.Phenotyping of minor blood groups (C,c,E,e,and Mi(a)) using a paper-based device and image-based high-throughput detection[J]. Anal Chim Acta,2023,1237: 340573.
[31] CHANG T C,YU J,WANG Z M,et al.Machine learning to optimize automated RH genotyping using whole-exome sequencing data[J]. Blood Adv,2024,8(11):2651-2659.
[32] ATTERBERRY B A,PALUCH P,LAMKINS A R,et al.Rapid acquisition of (103)Rh solid-state NMR spectra by (31)P detection and sideband selective methods[J]. J Am Chem Soc,2025,147(17):14411-14421.
[33] XU L,ZENG Q,LIANG L Q,et al.Generation of Rh D-negative blood using CRISPR/Cas9[J]. Cell Prolif, 2023,56(11):e13486.
[34] PETAZZI P,MIQUEL-SERRA L,HUERTAS S,et al.ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor-derived human-induced pluripotent stem cells[J]. Clin Transl Med, 2022,12(10):e1063.
[35] 中华医学会临床输血学分会,中华医学会围产医学分会. 孕产妇红细胞特殊血型抗原-抗体监测与输血管理专家共识[J]. 中华围产医学杂志,2022,25(10):721-728.
[36] 杨金华,任道菊,李小薇,等. 无创胎儿游离DNA RHE血型基因型诊断技术的准确性和可行性研究[J]. 中国输血杂志,2025,38(3):368-374.
[37] VAN 'T OEVER R M,VERWEIJ E J T,DE HAAS M. How I use noninvasive prenatal testing for red blood cell and platelet antigens[J]. Blood,2025,145(20):2266-2274.
[38] REGO S,ASHIMI BALOGUN O,EMANUEL K,et al.Cell-free DNA analysis for the determination of fetal red blood cell antigen genotype in individuals with alloimmunized pregnancies[J]. Obstet Gynecol,2024, 144(4):436-443.
[39] CALANDRINI C,VERHAGEN O J H M,TISSOUDALI A,et al. Real-world performance of a clinical droplet digital polymerase chain reaction assay for non-invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD,RhE,Rhc,RhC,K1,HPA-1a or HPA-5b: A 1-year experience[J]. Vox Sang,2025,120(2):170-177.
[40] HUI Y M T,GURUNG K,LAYTON D M,et al. Sickle cell disease patients in two London trusts: Genotyping including RH variants[J]. Transfus Med,2022,32(3): 210-220.
[41] ISRAELYAN N,VEGE S,FRIEDMAN D F,et al.RH genotypes and red cell alloimmunization rates in chronically transfused patients with sickle cell disease: A multisite study in the USA[J]. Transfusion,2024, 64(3):526-535.
[42] FLOCH A,TOURNAMILLE C,CHAMI B,et al.Genotyping in sickle cell disease patients: the French strategy[J]. Transfus Med Hemother,2018,45(4):264-270.
[43] 中国输血协会. 红细胞血型基因分型技术指南[S]. 2021.

Research Progress on the Molecular Regulatory Mechanism of the Rh Blood Group System and Its Clinical Application

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 14

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	ZHAO Xiaolin, ZHANG Chengxin, WANG Qiushi. A Case of Mixed Antibodies Against both Anti-Di^a and Anti-Wr^a [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(4): 552-556.
[2]	ZHAO Tongmao. RhCE Antigen Mismatch is the Main Risk for Chinese Transfusion Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(3): 289-290.
[3]	WANG Fei, WU Yunxiang, WANG Hua, ZUO Jiangtao, ZHAO Peizhe, ZHANG Xin, LI Zhicheng, ZHANG Demei. Miss Detection and Frequency of the D Variant in Initial RhD-negative Sample Screening [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(3): 373-377.
[4]	ZHENG Yan, WANG Wenting, YANG Longfei, WANG Qiong, MU Shijie. Serological Characteristics and DNA Sequence Analysis of Patients with RhD Variant [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 762-765.
[5]	LI Yan, ZHOU Liling, MA Zhaoze, ZHU Kaijie, WANG Chenlong. Genotypic Identification and Sequence Analysis of B/AB Subtypes in 25 Cases [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 787-791.
[6]	QIAO Yanhui, GWI WeiPeng, XU Baohong, MUYESAIER·Yisimayili. Analysis of 249 Cases with RhD Variant Phenotypes in Xinjiang [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 645-650.
[7]	LIU Hui, ZHUO Hailong, LUO Qun. Daratumomab Interference in Polybrene Test Due to IgG Anti-D Antibody [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(5): 625-630.
[8]	ZHONG Zhengrong, WANG Bo, YAN Ke, et al. Comparison of Coagulation and Myocardial Markers in Patients Infected with Different Omicron Variants [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 408-411.
[9]	YANG Qian, LU Hua, XU Ting. Develop a Quantum Dots Fluorescent Detection of RhD Blood Group [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(2): 188-192.
[10]	Xiang Dong, Fan Liang-feng, Liu Xi, et al. Analysis of 100 cases of immune hemolytic transfusion reaction [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(1): 11-15.
[11]	DING Meng-yuan, ZHOU Xiu, TANG Long-hai, et al. Molecular Genetic Analysis of 48 Cases with D Variant Phenotypes [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(1): 84-88.
[12]	WU Fan, LIANG Shuang, PENG Long, et al. RhCE Phenotyping and RHD Genotyping for 38 Blood Donors with weak D Phenotype [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(5): 632-638.
[13]	ZHAO Ling-jun. A Case Report of Forward/Reverse Blood Grouping Discrepancy Resulting from ABO Gene Variant [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2017, 19(2): 178-182.
[14]	XIAO Jian-yu, LI Ping, LU Le, et al. Study on Molecular Biology of Rh（D） Variants [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2016, 18(6): 524-527.